SYSTEMIC DISORDERS/CONDITIONS -Clinical Outcomes Studies

PSY1 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN
Aguiar-Ibáñez R 1 , Gauthier A 2 , Umuhire D 3 , Johnston JA 4 , Zhao Y 4 , Le TK 4 1 i3 Innovus, Uxbridge, Middlesex, UK, 2 Amaris, London, Middlesex, UK, 3 i3 Innovus, Nanterre, France, 4 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Chronic low back pain (CLBP) is a major cause of disability, affecting mainly working-age adults and imposing a large economic burden on society. Since no consensus exists regarding standard of care for this condition, the objective of this study was to systematically review the efficacy and safety of pharmacotherapies used for CLBP. METHODS: A systematic literature review was conducted through July/ August 2008, searching MEDLINE, EMBASE, and bibliographic details of relevant studies. Prospective trials and observational studies were included if they assessed pharmacotherapies in adults with CLBP and were written in English. Efficacy endpoints included: pain relief, pain interference with activities, individual's functioning and response to treatment. Adverse event (AE) rates and withdrawal rates due to AEs were also assessed. Extensive study heterogeneity prohibited quantitative synthesis. RESULTS: From 773 citations screened, 65 studies (published between 1982 and 2008) were selected, of which 54 were randomized controlled trials. The efficacy measures most consistently reported across studies included the visual analogue scale (VAS) and the Roland Morris Disability Questionnaire (RMDQ). Non-steroidal anti-inflammatory drugs (NSAIDs), weak and strong opioids, several antidepressants (clomipramine, mianserin, and duloxetine titrated based on patient response and tolerability), the anticonvulsant topiramate, and certain transdermal medications (transdermal fentanyl and lidocaine patches) significantly reduced pain intensity. The effectiveness of injections (i.e., glucose and lidocaine) and other antidepressants (paroxetine, trazodone or bupropion) was uncertain. Regarding patient functioning, significant improvements were observed for NSAIDs, opioids and duloxetine, but not for local injections. The magnitude of effect of these endpoints ranged from small to moderate, depending on the pharmacotherapy assessed. CONCLUSIONS: NSAIDs, opioids, some antidepressants, an anticonvulsant and certain transdermal medications seemed to significantly reduce pain intensity in CLBP, while inconclusive results were obtained for other antidepressants and local injections. Overall, the study findings were consistent with current guideline recommendations from Europe and US.
PSY2 EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE: ARE THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER PATIENTS?
Bharmal M 1 , Garvert W 2 , Jo H 2 , Gemmen EK 1 , Hall JR 3 1 Quintiles, Inc, Falls Church, VA, USA, 2 Quintiles, Inc., Falls Church, VA, USA, 3 Quintiles, Inc., Bracknell, UK OBJECTIVES: Propoxyphene is among the most commonly prescribed opioid analgesic in the elderly. However, many guidelines, including the American Geriatric Society and Beer's List of Potentially Inappropriate Medications, recommend restricting its use in that age group. These guidelines are based on expert opinions with limited empirical evidence. The objective of this study was to evaluate whether there were differences in adverse event reporting for propoxyphene by age group using a large post-marketing safety surveillance data. METHODS: Analysis was conducted using the 2005-2008 Adverse Event Reporting System (AERS) data in the US, which was developed to support the FDA's post-marketing safety surveillance program for all approved products. Adverse events reported with propoxyphene as primary, secondary or interacting drug were categorized into central nervous system (CNS) and gastrointestinal (GI) adverse events (AEs). Logistic regressions were used to assess the risk of CNS and GI adverse events (AEs) among the elderly (age 65) and younger patients (age 65) controlling for gender and those reporting the AEs. Proportional reporting ratios (PRR) for the propoxyphene-AE combination were also computed for the elderly and younger patients. RESULTS: In the period 2005-2008, a total of 2497 propoxyphene-AE combinations were reported, 261 were CNS-related and 127 were GI-related. In multivariate analysis, controlling for gender and those reporting the AEs, no significant differences were observed in the risk of CNS-related AEs (Odds ratio: 0.827; 95% CI: 0.619-1.105; p 0.199) or GI-related AEs (Odds ratio: 1.216; 95% CI: 0.832-1.778; p 0.313) among elderly versus young patients. Among the elderly, the PRR for propoxyphene-CNS AEs was 0.795 and the PRR for propoxyphene-GI AEs was 0.596. These were similar to the PRRs among younger patients, which were 0.700 and 0.439, respectively. CONCLUSIONS: Using a voluntary postmarketing surveillance database, the study found no differences in the extent of CNS AEs and GI AEs reported with propoxyphene among elderly patients versus younger patients.
PSY3 DETERMINING THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE
Padula WV, Nair KV University of Colorado at Denver and the Health Sciences Center, Aurora, CO, USA OBJECTIVES: To determine payments made by commercial health care providers for adults diagnosed with obesity, and those who are comorbid with any combination of the following chronic conditions: diabetes mellitus (DM), hypertension, depression, and/or congestive heart failure (CHF). METHODS: We utilized a 10% random sampling from a commercial claims and encounters database (n 12,416,190) . The study population (n 50,717) was limited to those who: 1) were adults age 18-64; 2) filed a claim between 2006-2007; 3) had at least one inpatient visit, one outpatient visit, or one emergency department visit; and; 4) had been given a primary or secondary diagnosis of obesity. Persons were identified and categorized if they had one or more comorbid diagnoses (DM, hypertension, depression, and/or CHF) in addition to obesity. After adjusting for age and gender, we calculated the mean total net expenditures (in $US 2007) for each combination of comorbid conditions. All calculations were performed in Stata. RESULTS: Among those diagnosed with obesity, the mean net expenditures for services were $1799 per patient. Persons diagnosed with obesity and other comorbidities observed an increase in total net expenditures. Obesity and hypertension observed the highest increase among single comorbidities at $4298. For persons with obesity and two other comorbidities, DM and depression was the highest at $14,364. The most expensive condition in the study sample was obesity, DM, hypertension and depression at $14,843. All results were statistically significant at the 95% confidence level. CONCLUSIONS: Compared to the average medical claim, persons diagnosed with obesity along with other common chronic conditions experience significant increases in health care costs. These costs are often driven higher by the time spent as inpatients. In many cases, obesity may be the cause of other chronic conditions that result in these high costs. Thus, by controlling and reducing the prevalence of obesity, we may see significant decreases in health care expenditures.
PSY4 CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA
Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B Erasmus MC, Rotterdam, The Netherlands OBJECTIVES: Treatment of patients with acute myeloid leukemia (AML) is based upon stratification into risk (prognosis) groups. New diagnostic methods are in development to improve this stratification. Economic evaluations of these methods require knowledge of what happens when the current stratification methods are used. We examined whether the literature can provide valid estimates for the outcomes of complete remission rates for patients with primary AML aged 16-60 years. METHODS: A systematic literature review was performed using Pubmed and Embase. Inclusion criteria were: 100 AML patients and detailed outcomes per risk group (favorable, intermediate, unfavorable) . Excluded were: Phase I/II studies, studies not containing any patients aged 16-60 years or with primary AML. We compared various study characteristics such as patient population, treatment given, risk group definitions and complete remission (CR) rates as outcome. A chi-square test for homogeneity of CR rates was performed. RESULTS: Twelve studies fulfilled the eligibility criteria. Great variation was found between study populations. While treatment varied between the studies, all patients received cytarabine and an anthracycline. Definitions of risk groups varied greatly except for the favorable risk group. There was no homogeneity in overall CR rate (range: 52-85% p 0.001). After excluding studies with many patients other than the target population, heterogeneity between the remaining studies decreased (N 7, p 0.083). CR rates were homogeneous in the favorable group (p 0.223), but heterogeneous in the intermediate and unfavorable groups (p 0.044 and p 0.096 respectively). CONCLUSIONS: Differences in patient population and
